Health TrialsbyHealthPanel

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors

This study employs a non-randomized, open-label design to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of DC50292A tablets in patients with MTAP-deficient advanced or metastatic solid tumors. The study consists of two parts: dose escalation and dose expansion.

Participants needed: 32
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Heronova PharmaceuticalsUpdated: Sep 16, 2026Locations: 8
Eligibility criteria

Voluntarily signs the informed consent form, demonstrates understanding of the s... [+8]

Received chemotherapy, radiotherapy, biologics, endocrine therapy, immunotherapy... [+24]

Read more
Status: Recruiting

A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors

This study is a multicenter, open-label, cohort expansion Phase Ib/IIa trial designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profile of DC05F01 in patients with recurrent/refractory ovarian cancer and other advanced solid tumors.

Participants needed: 60
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Heronova PharmaceuticalsUpdated: Sep 16, 2026Locations: 2
Eligibility criteria

Voluntarily signed the informed consent form, understanding the study and willin... [+6]

Received any other investigational drug or treatment in another clinical trial w... [+17]

Read more
Status: Recruiting

A Study of DC6001 Tablet in Healthy Chinese Adult Subjects

This study adopts a randomized, double-blind, parallel placebo-controlled dose-escalation design, consisting of two parts: Part 1 includes a single ascending dose (SAD) study plus a food effect (FE) study, and Part 2 is a multiple ascending dose (MAD) study.

Participants needed: 76
Trial details
Phase: Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: Heronova PharmaceuticalsUpdated: Feb 18, 2026Locations: 1
Eligibility criteria

Healthy volunteers aged 18-55 years (inclusive) at the time of signing the infor... [+4]

Subjects with clinically significant abnormalities or diseases occurring within... [+20]

Read more